anti
-
Anti-trust authorities approve Bosch’s acquisition of Eisai Machinery
Bosch finalized the acquisition of the machinery business companies of Eisai, one of the leading Japanese pharmaceutical companies based in Tokyo. The transaction has been approved by the antitrust authorities without further restrictions.
anti | 14 May 2012
-
More investment needed in anti-obesity drugs
Pharmaceutical companies should increase their investment in anti-obesity drug therapies to support the growing number of clinically obese individuals worldwide, a report by GlobalData has found.
anti | 01 May 2012
-
AB SCIEX launches workhorse mass spectrometer for routine quantitation, screening
This system from AB SCIEX was developed based on feedback from scientists and application experts in analytical science that led to intelligently re-engineering the company’s existing API 4000.
anti | 04 April 2012
-
ArQule announces tivantinib meets primary endpoint
ArQule announces tivantinib meets primary endpoint, significantly extending time to progression in Phase 2 trial in second-line hepatocellular carcinoma.
anti | 13 March 2012
-
Boehringer Ingelheim single combination of telmisartan and amlodipine provides 24-hour blood pressure reduction and control
Boehringer Ingelheim has released a new anti-hypertensive drug (TWYNSTA) containing a unique combination of telmisartan and amlodipine. Very often, hypertension sufferers take up to four drugs to reach an acceptable blood pressure (BP) more effectively. The single-pill combination drug is taken once daily and provides additional therapeutic and cardiovascular (CV) benefits.
anti | 02 February 2012
-
Forest Laboratories and Gedeon Richter announce positive results with investigational antipsychotic agent
Data showed that cariprazine-treated patients with acute manic episodes experienced significant symptom improvement compared to placebo-treated patients.
anti | 05 October 2011
-
Bristol-Myers Squibb and Ono enter into strategic agreement for anti-PD-1 antibody
Companies also form strategic alliance for the co-development and co-commercialization of ORENCIA (abatacept) in Japan.
anti | 21 September 2011
-
Rib-X, Sanofi sign research collaboration agreement on antibiotics
Novel technology targets bacterial ribosomes creating an entirely new class of antibiotic therapeutics.
anti | 11 July 2011
-
Sanofi, Rib-X sign research collaboration agreement on antibiotics
Sanofi announced the signing of an exclusive worldwide research collaboration agreement and option for license with Rib-X Pharmaceuticals Inc for novel classes of antibiotics resulting from Rib-X's RX-04 program for the treatment of resistant Gram-po…
anti | 01 July 2011
-
Quantitative, qualitative analysis
AB SCIEX SelexION technology delivers a dimension of selectivity in diff erential ion mobility spectrometry for quantitative and qualitative analysis. This diff erential ion mobility separation technology possesses day-to-day reproducibility, robustn…
anti | 01 July 2011
